Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 10, 2013, Pages 743-754

  Lopes Virella, Maria F ^a,b   Virella, Gabriel ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Autoimmunity; Immune complexes; Modified LDL; Modified LDL antibodies

Indexed keywords

FC RECEPTOR; HEXANOYL LYSINE LOW DENSITY LIPOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; METHYLGLYOXAL LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; ENZYME IMMUNOASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR;

ANTIGEN-ANTIBODY COMPLEX; ATHEROSCLEROSIS; AUTOANTIBODIES; CELL LINE; HUMANS; LIPOPROTEINS, LDL; PHAGOCYTOSIS;

EID: 84886645705     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.19281     Document Type: Review

References (105)

1. Libby P: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol, 2012; 32: 2045-2051.
2. Ketelhuth DF, Hansson GK: Cellular immunity, lowdensity lipoprotein and atherosclerosis: Break of tolerance in the artery wall. Thromb Haemost, 2011; 106: 779-786.
3. Lundberg AM, Hansson GK: Innate immune signals in atherosclerosis. Clin Immunol, 2010; 134: 5-24.
4. Andersson J, Libby P, Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol, 2010; 134: 33-46.
5. Lopes-Virella MF, Virella G: Clinical significance of the humoral immune response to modified LDL. Clin Immunol, 2010; 134: 55-65.
6. Penn MS, Chisolm GM: Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis, 1994; 108: S21-29.
7. Henriksen T, Mahoney ME, Steinberg D: Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis, 1983; 3: 149-158.
8. Arai K, Kita T, Yokode M, Narumiya S, Kawai C: Multiple receptors for modified LDL in mouse peritoneal macrophages: Different uptake mechanisms for acetylated and oxidized LDL. Biochem Biophys Res Commun, 1989; 159: 1375-1379.
9. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: Cd36 is a receptor for oxidized LDL. J Biol Chem, 1993; 268: 11811-11818.
10. Sparrow CP, Parthasarathy S, Steinberg D: A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem, 1989; 264: 2599-2604.
11. Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL: Cd36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest, 2010; 120: 3996-4006.
12. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Nat Acad Sci USA, 1987; 84: 2995-299.
13. Quinn MT, Parthasarathy S, Steinberg D: Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of lowdensity lipoprotein. 82: 5949-5953, 1985. Proc Natl Acad Sci USA, 1985; 82: 5949-5953.
14. Berliner JA, Territo MC, Sevanian A, Raimin S, Kim JA, Bamshad B, Ester-son M, Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest, 1990; 85: 1260-1266.
15. Kume N, Cybulsky MI, Gimbrone MAJ: Lysophosphatidyl- choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest, 1992; 90: 1138-1144.
16. Kahn BV, Parthasarathy SS, Alexander RW, Medford RM: Modified LDL and its constituents augment cytokine- activated vascular cell adhesion molecule -1 gene expression in human vascular endothelial cells. J Clin Invest, 1995; 95: 1262-1270.
17. Takei A, Huang Y, Lopes-Virella MF: Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis, 2001; 154: 79-86.
18. Svensson PA, Asea A, Englund MC, Bausero MA, Jernas M, Wiklund O, Ohlsson BG, Carlsson LM, Carlsson B: Major role of hsp70 as a paracrine inducer of cytokine production in human oxidized LDL treated macrophages. Atherosclerosis, 2006; 185: 32-38.
19. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A, 2002; 99: 15596-15601.
20. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: Insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep, 2002; 4: 228-237.
21. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest, 1994; 70: 138-151.
22. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule- 1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest, 1995; 96: 1395-1403.
23. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK: Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J Lipid Res, 1984; 25: 1109-1116.
24. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis, 1990; 10: 325-335.
25. Steinbrecher UP: Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem, 1987; 262: 3603-3608.
26. Mironova M, Virella G, Lopes-Virella MF: Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol, 1996; 16: 222-229.
27. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley DH, Wagner F, Lopes-Virella MF, Group DER: Autoimmune response to advanced glycosylation endproducts of human low density lipoprotein. J Lipid Res, 2003; 443: 487-493.
28. Atchley DH, Lopes-Virella MF, Zheng D, Virella G: Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia, 2002; 45: 1562-1571.
29. Virella G, Lopes-Virella MF: Lipoprotein autoantibodies: Measurement and significance. Clin Diagn Lab Immunol, 2003; 10: 499-505.
30. Virella G, Thorpe S, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF: Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res, 2004; 45: 1859-1867.
31. Beaumont J: Autoimmune hyperlipidemia. An atherogenic metabolic disease of immune origin. Rev Eur Stud Clin Biol, 1970; 15: 1037-1041.
32. Füst G, Szondy E, Szekely J, Nanai I, Gerö S: Studies on the occurrence of circulating immune complexes in vascular disease. Atherosclerosis, 1978; 29: 181-190.
33. Klimov AN, Denisenko AD, Popov AV, Nagornev VA, Pleskov VM, Vinogradov AG, Denisenko TV, Magracheva E, Kheifes GM, Kuznetzov AS: Lipoprotein-antibody immune complexes: Their catabolism and role in foam cell formation. Atherosclerosis, 1985; 58: 1-15.
34. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF: Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med, 1988; 168: 1041-1059.
35. Klimov AN, Denisenko AD, Vinogradov AG, Nagornev VA, Pivovarova YI, Sitnikova OD, Pleskov VM: Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis, 1988; 74: 41-46.
36. Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT: Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb, 1991; 11: 1356-1367.
37. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G: The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc gamma RI receptor. Atherosclerosis, 1997; 135: 161-170.
38. Abdelsamie SA, Li Y, Huang Y, Lee M-H, Klein RL, Virella G, Lopes-Virella MF: Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptor I. Clin Immunol, 2011; 139: 258-266.
39. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes- Virella MF: OxLDL immune complexes activate complement and induce cytokine production by monomac 6 cells and human macrophages. J Lipid Res, 2006; 47: 1975-1983.
40. Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF: Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol, 2000; 20: 2533-2538.
41. Nagarajan S: Anti-oxLDL IgG blocks oxLDL interaction with CD36, but promotes FcgR, CD32a-dependent inflammatory cell adhesion. Immunol Lett, 2007; 108: 52-61.
42. Morganelli PM, Kitzmiller TJ, Hemmer R, Fanger MW: Redirected targeting of LDL to human monocyte Fcg receptors with bispecific antibodies. Arterioscler Thromb, 1992; 12: 1131-1138.
43. Virella G, Munoz JF, Galbraith GM, Gissinger C, Chassereau C, Lopes-Virella MF: Activation of human monocyte- derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopath, 1995; 75: 179-189.
44. Kiener PA, Rankin BM, Davis PM, Yocum SA, Warr GA, Grove RI: Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol, 1995; 15: 990-999.
45. Gisinger C, Virella GT, Lopes-Virella MF: Erythrocytebound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocytederived macrophages. Clin Immunol Immunopath, 1991; 59: 37-52.
46. Virella G, Atchley DH, Koskinen S, Zheng D, Lopes- Virella M: Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol, 2002; 105: 81-92.
47. Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, Pentikainen MO: OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol, 2006; 26: 576-583.
48. Hammad SM, Twal WO, Barth JL, Smith KJ, Saad AF, Virella G, Argraves WS, Lopes-Virella MF: Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis, 2009; 202: 394-404.
49. Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM: Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: Role in phagocytosis and cytokine release. Immunology, 2012; 136: 30-45.
50. Al Gadban MM, Smith KJ, Soodavar F, Piansay C, Chassereau C, Twal WO, Klein RL, Virella G, Lopes-Virella MF, Hammad SM: Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: Impact on oxidative stress. PLoS One, 2010; 5.
51. Virella G, LI Y, Huang Y, Lopes-Virella M: The nature of modified LDL involved in the formation of immune complexes has a modulating effect on macrophage activation. FOCIS 2012. 2012; Abstract supplement: 94-95.
52. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest, 1989; 84: 1086-1095.
53. Yla-Herttuala S, Palinski W, Rosenfeld ME, Steinberg D, Witztum JL: Lipoproteins in normal and atherosclerotic aorta. European Heart J, 1990; 11: 88-89.
54. Yla-Herttuala S: Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Ann Med, 1991; 23: 561-567.
55. Yla-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain igg that recognizes epitopes of oxidized LDL. Arterioscler Thromb, 1994; 14: 32-40.
56. Turk Z, Ljubic S, Turk N, Benko B: Detection of autoantibodies against advanced glycation endproducts and age-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta, 2001; 303.
57. Bevan RJ, Durand MF, Hickenbotham PT, Kitas GD, Patel PR, Podmore ID, Griffiths HR, Waller HL, Lunec J: Validation of a novel ELISA for measurement of MDA-LDL in human plasma. Free Radic Biol Med, 2003; 35: 517-527.
58. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D: Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest, 1995; 95: 2611-2619.
59. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund O: Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 1998; 18: 1203-1211.
60. van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM: Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis, 1996; 122: 245-253.
61. Tsimikas S, Palinski W, Witztum JL: Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptordeficient mice. Arterioscler Thromb Vasc Biol, 2001; 21: 95-100.
62. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol, 1999; 90: 165-172.
63. Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF: Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopath, 1997; 85: 73-82.
64. Turk Z, Sesto M, Skodlar J, Ferencak G, Turk N, Stavljenic- Rukavina A: Soluble LDL-immune complexes in type 2 diabetes and vascular disease. Horm Metab Res, 2002; 34: 196-201.
65. Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF: Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol, 2005; 12: 68-75.
66. Zubler RH, Perin LH, Creighton WD, Lambert PH: Use of polyethylene glycol (PEG) to concentrate immune complexes from serum or plasma samples. Ann Rheum Dis, 1977; 36 (Suppl.): 23-26.
67. Amir S, Binder CJ: Experimental immunotherapeutic approaches for atherosclerosis. Clin Immunol, 2010; 134: 66-79.
68. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. ArteriosclerThromb Vasc Biol, 1998; 18: 1972-1982.
69. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL: Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol, 1995; 15: 1569-1576.
70. Virella G, Lopes-Virella MF: Humoral immunity and atherosclerosis. Nature Medicine, 2003; 9: 243-244.
71. Davis MM: A prescription for human immunology. Immunity, 2008; 29: 835-838.
72. Turner MW: Structure and function of immunoglobulins. In: Glynn LE, Steward MM, eds. Immunochemistry: An advanced textbook. New York: J. Wiley and Sons; 1977: 1-57.
73. Boackle RJ: The complement system. In: Virella G, ed. Medical immunology. NY and London: Informa; 2007: 93-112.
74. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S: Immunoglobulin m type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation, 2003; 108: 2107-2112. Epub 2003 Oct 2106.
75. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J: Antibodies of igm subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis, 2006; 188: 160-166.
76. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB: Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res, 2007; 48: 425-433.
77. Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, Shah PK, Nilsson J: Association between igm against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke, 2007; 38: 1495-1500.
78. Virella G, Colglazier J, Chassereau C, Hunt KJ, Baker NL, Lopes-Virella MF: Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem, 2013; 34: 61-74.
79. Lopes-Virella MF, Baker NL, Hunt KJ, Virella G, and Moritz T for the VADT Group of Investigators: The levels of MDA - LDL in circulating immune complexes predict myocardial infarction in the VADT study Atherosclerosis, 2012; 224: 526-532.
80. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J: Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol, 1998; 18: 100-107.
81. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R: Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol, 2000; 20: 2243-2247.
82. Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y: The oxidation ratio of LDL: A predictor for coronary artery disease. Dis Markers, 2008; 24: 341-349.
83. Anselmi M, Garbin U, Agostoni P, Fusaro M, Pasini AF, Nava C, Keta D, Turri M, Zardini P, Vassanelli C, Lo Cascio V, Cominacini L: Plasma levels of oxidized-lowdensity lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis, 2006; 185: 114-120.
84. Yamashita H, Ehara S, Yoshiyama M, Naruko T, Haze K, Shirai N, Sugama Y, Ikura Y, Ohsawa M, Itabe H, Kataoka T, Kobayashi Y, Becker AE, Yoshikawa J, Ueda M: Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J, 2007; 71: 681-687.
85. Niccoli G, Mongiardo R, Lanza GA, Ricco A, Burzotta F, Trani C, Mazzari MA, Liuzzo G, Lombardo A, Rebuzzi AG, Holvoet P, Crea F: The complex link between oxidised low-density lipoprotein and unstable angina. J Cardiovasc Med (Hagerstown), 2007; 8: 387-391.
86. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR: The relationship between oxidized LDL and other cardiovascular risk factors and subclinical cvd in different ethnic groups: The multi-ethnic study of atherosclerosis (mesa). Atherosclerosis, 2007; 194: 245-252.
87. Romano EL, Sotolongo-Pons M, Camejo G, Soyano A: Circulating immune complexes, immunoglobulins, complement, antibodies to dietary antigens, cholesterol and lipoproteins levels in patients with occlusive coronary lesions. Atherosclerosis, 1984; 53: 119-128.
88. Smith GW, McArthur CJ, Simpson IJ: Circulating immune complexes in myocardial infarction. J Clin Lab Immunol, 1983; 12: 197-199.
89. Virella G, Wohltmann H, Sagel J, Lopes-Virella MF, Kilpatrick M, Phillips C, Colwell J: Soluble immune complexes in patients with diabetes mellitus: Detection and pathological significance. Diabetologia, 1981; 21: 184-191.
90. Orekhov AN, Kalenich OS, Tetov VV, Novikov ID, Vorobeva EG: Cholesterol level in circulating immune complexes as a marker of coronary atherosclerosis. In: Malmendier CL, ed. Hypercholesterolemia, hypochlesterolemia, hypertriglyceridemia. New York: Plenum Press; 1990: 393-397.
91. Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN: Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Path, 1990; 52: 300-308.
92. Szondy E, Horvath M, Mezey Z, Szekely J, Lengyel E, Fust G, Gero S: Free and complexed anti-lipoprotein antibodies in vascular diseases. Atherosclerosis, 1983; 49: 69-77.
93. Boullier A, Hamon M, Walters-Laporte E, Martin- Nizart F, Mackereel R, Fruchart JC, Bertrand M, Duriez P: Detection of autoantibodies against oxidized lowdensity lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta, 1995; 238: 1-10.
94. Wu R, de Faire U, Lemne C, Witztum JL, Frostegard J: Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension, 1999; 33: 53-59.
95. Salonen E-M, Vaheri A, Suni J, Wagger O: Rheumatoid factor in acute viral infections: Interference with determination of IgM, IgG, and IgA antibodies in an enzyme immunoassay J Inf Dis, 1980; 142: 250-255.
96. Tinahones FJ, Gomez-Zumaquero JM, Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, Esteva I, de Adana MS, Cardona F, Soriguer F: Influence of age and sex on levels of anti-oxidized LDL antibodies and anti- LDL immune complexes in the general population. Journal of lipid research, 2005; 46: 452-457.
97. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL: Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol, 2003; 41: 360-370.
98. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein bB-100 in patients with acute coronary syndromes in the miracl trial. Circulation, 2004; 110: 1406-1412.
99. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G: Immune complexes containing modified lipoproteins are related to the progression of internal carotid intimamedia thickness in patients with type 1 diabetes. Atherosclerosis, 2007; 190: 359-369.
100. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G: The levels of oxidized LDL and age- LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes, 2011; 60: 582-589.
101. Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G: Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis, 2011; 214: 462-467.
102. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation, 1998; 98: 1487-1494.
103. Fu D, Wu M, Chen Y, Du M, Zhang J, Li Y, Virella G, Wilson K, Boulton M, Ma J-X, Lopes-Virella MF, Chen J, Lyons TJ: Oxidized-LDL immunocomplexes are implicated in diabetic retinopathy. Diabetes, 2011; 60 (Suppl. 1): A53.
104. Lopes-Virella MF, Baker N, Hunt K, Lyons T.A. J, Virella G, group DEs: High concentrations of age-LDL and oxidized LDL in circulating immune complexes is associated with progression of retinopathy in type 1 diabetes. Diabetes care, 2012; 35: 1333-1340.
105. Virella G, Carter RE, Saad A, Crosswell EG, Game BA, Lopes-Virella MF: Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol, 2008; 127: 394-400